Healthcare / BiotechnologyParis
$1.25
-0.02 (-2.45%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-4.1M · quality 62.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$18M
P/E
N/A
•EV/EBITDA
N/A
•ROE
36.2%
↑Gross Margin
-15.4%
↓Debt/Equity
-0.72
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+17.4%
FCF CAGR
—
FCF margin
-68.4%
FCF / Net income
0.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.0M · net income $-9.5M · FCF $-4.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.0M | $6.0M | $5.0M | $4.5M | $3.7M |
| Net Income | $-9.5M | $-9.5M | $-6.5M | $-7.5M | $-10.3M |
| EBITDA | $-7.9M | $-7.9M | $-6.3M | $-6.3M | $-9.8M |
| EPS | — | — | -0.31 | -0.60 | -1.05 |
| Gross Margin | -15.4% | -15.4% | -23.6% | -49.8% | -144.9% |
| Operating Margin | -139.1% | -139.1% | -182.2% | -145.2% | -276.8% |
| Net Margin | -158.7% | -158.7% | -130.0% | -168.9% | -276.4% |
| Balance Sheet | |||||
| Debt/Equity | -0.72 | -0.72 | -0.95 | -1.45 | -1.77 |
| Current Ratio | 0.48 | 0.48 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.1M | $-4.1M | $-853000.00 | $-7.3M | $-9.3M |
| Returns | |||||
| ROE | 36.2% | 36.2% | 33.9% | 59.7% | 97.8% |
| Growth & Yield | |||||
| Revenue Growth | 20.8% | 20.8% | 11.6% | 20.0% | — |
| EPS Growth | — | — | 48.3% | 42.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-50.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.31 → n/d
Residual
-50.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.